Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.71 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.67 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.67 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7546767 | 1.00 | GPBAR1 (0.71) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL2369521 | 1.00 | GPBAR1 (0.71) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL1758946 | 0.96 | GPBAR1 (0.67) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL2467588 | 0.96 | GPBAR1 (0.72) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL25791216 | 0.96 | GPBAR1 (0.75) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL25791236 | 0.96 | GPBAR1 (0.75) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL2637801 | 0.96 | GPBAR1 (0.75) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL8646650 | 0.95 | GPBAR1 (0.66) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL2323981 | 0.94 | GPBAR1 (0.78) | GPBAR1NR1H4SLC10A2PDE3ATBXA2R | |
| SCHEMBL1287858 | 0.93 | GPBAR1 (0.78) | GPBAR1NR1H4SLC10A2PDE3ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101480402-B | Cycloartenyl ferulate pharmaceutical composition and preparation method thereof | BEIJING CENTURY BIOCOM PHARMACEUTICAL TECHNOLOGYCO LTD | 2012-05-23 | — | — | CN | claimed |
| US-20240216467-A1 | DOSAGE REGIME FOR APOLIPOPROTEIN FORMULATIONS | CSL LTD (AU) | 2024-07-04 | — | — | US | disclosed |
| US-11732028-B2 | Contaminant removal method | CSL LIMITED (AU) | 2023-08-22 | — | — | US | disclosed |
| US-11723953-B2 | Reconstituted high density lipoprotein formulation and production method thereof | CSL LIMITED (AU) | 2023-08-15 | — | — | US | disclosed |
| EP-2793913-B1 | DOSAGE REGIME FOR APOLIPOPROTEIN FORMULATIONS | CSL LTD (AU) | 2023-06-21 | — | — | EP | disclosed |
| US-11427869-B2 | T cell balance gene expression, compositions of matters and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220133852-A1 | RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF | CSL LIMITED (AU) | 2022-05-05 | — | — | US | disclosed |
| US-11058747-B2 | Reconstituted high density lipoprotein formulation and production method thereof | CSL LIMITED (AU) | 2021-07-13 | — | — | US | disclosed |
| US-20210147509-A1 | CONTAMINANT REMOVAL METHOD | CSL LIMITED (AU) | 2021-05-20 | — | — | US | disclosed |
| US-10730927-B2 | Contaminant removal method | CSL LIMITED (AU) | 2020-08-04 | — | — | US | disclosed |
| US-20140378376-A1 | Dosage Regime for Apolipoprotein Formulations | CSL LIMITED (AU) | 2014-12-25 | — | — | US | disclosed |
| EP-2793913-A1 | DOSAGE REGIME FOR APOLIPOPROTEIN FORMULATIONS | CSL Limited (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20130190226-A1 | RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF | CSL LIMITED | 2013-07-25 | — | — | US | disclosed |
| WO-2013090978-A1 | DOSAGE REGIME FOR APOLIPOPROTEIN FORMULATIONS | CSL LIMITED (AU) | 2013-06-27 | — | — | WO | disclosed |
| EP-2588113-A1 | A RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF | CSL Limited (AU) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012000048-A1 | A RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF | CSL LIMITED (AU) | 2012-01-05 | — | — | WO | disclosed |
| US-20090105461-A1 | Calicheamicin conjugates | WYETH (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1740216-A2 | ANTIBODY CALICHEAMICIN CONJUGATES | Wyeth a Corporation of the State of Delaware (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060002942-A1 | Calicheamicin conjugates | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2005089808-A2 | ANTIBODY CALICHEAMICIN CONJUGATES | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060002942-A1 | Calicheamicin conjugates | CLSPN, CALU, CALR | GPBAR1 3701/4885NR1H4 2871/4885SLC10A2 1280/4885 |
| US-20090105461-A1 | Calicheamicin conjugates | CLSPN, CALU, CALR | GPBAR1 3701/4885NR1H4 2871/4885SLC10A2 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.